Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ME-401 (Zandelisib) Monotherapy and Combinations in B-cell Malignancies
NCT02914938Phase 1Terminated
- Sponsor
- MEI Pharma
- Start
- Oct 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of zandelisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL) and 4 more (3 arms), sponsored by MEI Pharma. Primary endpoints: Minimum Biologically Effective Dose at 1 year, Maximally Tolerated Dose at 1 year and 2 more. Started Oct 2016; status: terminated.
02
Drugs
zandelisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)follicular lymphoma (FL)marginal zone lymphoma (MZL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02914938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914938.